Informations générales (source: ClinicalTrials.gov)
Phylogenetic Analysis of Intra-tumor Molecular Heterogeneity on a Pilot Series of Diffuse Low-grade Multilobar Gliomas: Tumor Ontogenesis and Therapeutic Implications
Observational
University Hospital, Montpellier (Voir sur ClinicalTrials)
juin 2019
décembre 2020
29 juin 2024
Low-grade diffuse glioma (GDBG) are rare tumors of young adults, whose ontogenesis is
poorly understood. Patient management is based on the molecular profile defined by two
molecular markers : mutations of the IDH genes and chromosomal 1p19q co-deletion. To
date, the IDH and 1p19q statuses are determined on a single fragment collected from the
tumor. In the case of GDBGs infiltrating several brain lobes, the sampling is done
randomly on only one of the infiltrated lobes. An intra-tumoral heterogeneity of genetic
alterations has been suggested and would impact management.
Phylogenetic analysis of genetic alterations found, by high throughput sequencing, in
each lobe invaded by the same GDBG will make it possible to assess intra-tumoral
heterogeneity and to discuss, at a fundamental level, the hypothesis of a single tumor
site with secondary diffusion or that of the convergent progression of two or three
distinct tumor sites. Clinically, understanding the ontogenesis of GDBGs will improve
their management because of the known link between brain location, dominant molecular
profile, and prognosis.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Gui de Chauliac - 34295 - Montpellier - France | Catherine GOZE, Pharm-D; PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Be over 18 years old.
- Subject not opposed to participating in the study
- Be scheduled in the operating room for the first surgery of a low-grade diffuse
glioma presupposition on the basis of clinical and imaging criteria.
- Confirmation, after histopathological analysis of the resected tumor fragments, of
the diagnosis of grade II glioma according to the 2016 WHO classification of brain
tumors.
- Be over 18 years old.
- Subject not opposed to participating in the study
- Be scheduled in the operating room for the first surgery of a low-grade diffuse
glioma presupposition on the basis of clinical and imaging criteria.
- Confirmation, after histopathological analysis of the resected tumor fragments, of
the diagnosis of grade II glioma according to the 2016 WHO classification of brain
tumors.
- Patient minor, or major under legal protection, or unable to give consent.
- Refusal to participate in the study.
- Pathology diagnosis of grade III glioma according to WHO 2016 classification
- Have received oncology treatment (chemotherapy and or chemotherapy) before the first
surgery.